[Comment] The challenges of immunobridging without established correlates of vaccine-induced protection

Cervical cancer remains one of the top causes of cancer-associated morbidity and mortality among women in low-income and middle-income countries (LMICs), despite effective primary and secondary prevention methods being well known for more than a decade.1 In 2022, the Global Cancer Observatory reported 662 301 cases of cervical cancer and 348 874 cervical cancer-associated deaths worldwide, corresponding to an age-standardised incidence of 14 cases of cervical cancer per 100 000 women globally.2 This incidence is a far cry from WHO's elimination goal of fewer than four cervical cancer cases per 100 000 women.